GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly
2024年7月8日 - 9:15PM
ビジネスワイヤ(英語)
GordonMD® Global Investments today announced that portfolio
company Radionetics Oncology, a leader in developing targeted
radiopharmaceuticals for cancer treatment, has entered into a
strategic agreement with Eli Lilly and Company, (NYSE: LLY).
“We are thrilled to support Radionetics Oncology,” said Dr.
Craig Gordon, Chief Executive Officer of GordonMD®, who is also a
Board of Directors Observer for Radionetics. “Their dedication to
developing next-generation cancer treatments aligns perfectly with
our investment philosophy of fostering innovation in
healthcare.”
Under the terms of the agreement, San Diego-based Radionetics
received a $140 million upfront cash payment. As part of the
strategic arrangement, Lilly obtained the exclusive right to
acquire Radionetics upon conclusion of an exercise period for $1
billion.
Radionetics’ platform combines the power of radiopharmaceuticals
with the precision of small molecule targeting, offering a unique
approach to cancer treatment. Its pipeline focuses on small
molecule radioligands targeting GPCRs, a promising class of targets
with significant potential in oncology.
About GordonMD® Global Investments
GordonMD® Global Investments LP was founded in 2021 by Craig
Gordon, MD, a licensed physician with more than 13 years of
buy-side experience managing global biopharmaceutical portfolios.
The firm focuses on identifying differentiated investment
opportunities in biopharmaceutical companies primarily located in
the U.S., Europe and Japan. It currently provides investment
management and administrative services to a hedge fund investing
primarily in publicly traded companies as well as to two private
equity funds.
About Radionetics Oncology
Radionetics Oncology, Inc. is a clinical stage company focused
on the discovery and development of novel radiopharmaceuticals for
the treatment of a wide range of oncology indications and is poised
to capitalize on the increasing demand for novel radiotherapeutics.
Radionetics Oncology is supported by Frazier Life Sciences, 5AM
Ventures, DCVC Bio, Crinetics Pharmaceuticals, and GordonMD Global
Investments.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240708644984/en/
Media Contact: Jim Gold jgold@lumentus.com
347-968-2912